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The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), are emerging zoonotic paramyxoviruses that
can cause severe and often lethal neurologic and/or respiratory disease in a wide variety of mammalian hosts,
including humans. There are presently no licensed vaccines or treatment options approved for human or
veterinarian use. Guinea pigs, hamsters, cats, and ferrets, have been evaluated as animal models of human
HeV infection, but studies in nonhuman primates (NHP) have not been reported, and the development and
approval of any vaccine or antiviral for human use will likely require efficacy studies in an NHP model. Here,
we examined the pathogenesis of HeV in the African green monkey (AGM) following intratracheal inoculation.
Exposure of AGMs to HeV produced a uniformly lethal infection, and the observed clinical signs and pathology
were highly consistent with HeV-mediated disease seen in humans. Ribavirin has been used to treat patients
infected with either HeV or NiV; however, its utility in improving outcome remains, at best, uncertain. We
examined the antiviral effect of ribavirin in a cohort of nine AGMs before or after exposure to HeV. Ribavirin
treatment delayed disease onset by 1 to 2 days, with no significant benefit for disease progression and outcome.
Together our findings introduce a new disease model of acute HeV infection suitable for testing antiviral
strategies and also demonstrate that, while ribavirin may have some antiviral activity against the henipavi-
ruses, its use as an effective standalone therapy for HeV infection is questionable.
Hendra virus (HeV) and Nipah virus (NiV) are members of
the genus Henipavirus (family Paramyxoviridae) that can cause
severe respiratory illness and/or encephalitis in a wide variety
of mammals, including horses, pigs, and humans (7, 23). HeV
was identified as the causative agent of an acute respiratory
disease in horses in 1994 in Queensland, Australia (23), and to
date there have been 14 outbreaks in Australia since, with at
least one occurrence per year since 2006, most recently in May
2010 (ProMed-mail no. 20100522.1699 [International Society
for Infectious Diseases, http://www.promedmail.org]). Every
outbreak of HeV has involved horses as the initial infected
host, and there have been a total of seven human cases arising
from exposure to infected horses. Four human fatalities have
occurred (22), with the most recent occurring in August of
2009 (ProMed-mail no. 20090826.2998 and 20090903.3098).
All patients initially presented with influenza-like illnesses
(ILIs) after an incubation period of 7 to 16 days. While two
individuals recovered from ILI, one patient developed pneu-
monitis and died from multiorgan failure. Three of the lethal
cases developed encephalitic manifestations (mild confusion
and ataxia), with two patients experiencing seizures (22,
23, 27).
Data on the histopathology of fatal human HeV cases are
limited, but the pathology includes small necrotic plaques in
the cerebrum and cerebellum, in addition to mild parenchymal
inflammation (21, 27). Severe parenchymal inflammation and
necrosis were observed in the lungs. More extensive his-
topathologic data are available from 32 autopsies of fatal hu-
man NiV cases (28). Similarly to the HeV cases, pathology was
characterized by systemic vasculitis and parenchymal necrosis
in the central nervous system (CNS), while in the lung, patho-
logical findings mainly included vasculitis, fibrinoid necrosis,
alveolar hemorrhage, pulmonary edema, and aspiration pneu-
monia. Other organs that were affected included heart, kidney,
and spleen and showed generally mild or focal inflammation.
The development of syncytial multinucleated endothelial cells
is characteristic of both HeV and NiV (27, 28). At present, the
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details of the pathogenesis and histopathological changes me-
diated by either HeV or NiV infection in humans are naturally
derived from only the late phases of the disease course, and
therefore a relevant animal model is needed that mimics the
disease progression seen in humans.
Pteropid fruit bats, commonly known as flying foxes in the
family Pteropodidae, are the principle natural reservoirs for
both NiV and HeV (reviewed in reference 3). However, these
henipaviruses display a broad species tropism, and in addition
to bats, horses and humans, natural and/or experimental infec-
tion of HeV has been demonstrated in guinea pigs, hamsters,
pigs, cats, and ferrets (25). Experimental infections of Syrian
hamsters with HeV is lethal, and animals show disease similar
to that of human cases, including respiratory and neurological
symptoms, depending on the dose (11; unpublished data). In
this model, viral RNA can be detected in various organs of
infected hamsters, including brain, lung, kidney, heart, liver,
and spleen. The main histopathological findings included pa-
renchymal infection in various organs, including the brain, with
vasculitis and syncytial multinucleated endothelial cells in
many blood vessels (11). While this model is useful in studying
pathogenesis, it is limited in the availability of reagents to
do so.
There are currently no vaccines or treatments licensed for
human use. Several in vitro studies have shown that ribavirin is
effective against both HeV and NiV infection (1, 2, 29). An
open-label ribavirin treatment trial was run during an outbreak
of NiV in Malaysia in 1998 and reported to reduce mortality by
36% (6). Of the seven recorded human HeV cases, three
patients were treated with ribavirin, one of whom survived
(22). In the most recent outbreak of HeV in Australia, three
additional people received ribavirin treatment in combination
with chloroquine after suspected exposure to HeV-contami-
nated secretions from infected horses. While all three individ-
uals survived, infection was not confirmed, and therefore it
remains unknown whether the treatment had any beneficiary
effect (ProMed-mail no. 20090826.2998). In addition, two an-
imal studies in hamsters showed that ribavirin treatment delays
but does not prevent death from NiV or HeV infection (8, 10).
Therefore, an animal model with greater relevance to humans
and that recapitulates the disease processes seen in human
cases of HeV is needed to get a better answer to whether
ribavirin might be effective against henipavirus infections. In
addition, the U.S. FDA implemented the “Animal Efficacy
Rule,” which specifically applies to the development of thera-
peutic products when human efficacy studies are not possible
or ethical, such as is often the case with highly virulent patho-
gens like HeV (24). Essentially, this rule allows for the evalu-
ation of vaccines or therapeutics using data derived from stud-
ies carried out in at least two animal models. The licensure of
any therapeutic modalities for HeV will require a thorough
evaluation of HeV pathogenesis in nonhuman primates
(NHPs).
In the present study, we report the development and char-
acterization of a new nonhuman primate (NHP) model of
lethal HeV infection in the African green monkey (AGM).
The pathogenesis and disease progression in the AGM upon
HeV infection essentially mirrored the lethal disease episodes
seen among human cases of HeV. Using this new model, the
efficacy of ribavirin treatment against lethal challenge with
HeV was examined. Here we have shown that ribavirin treat-
ment can significantly delay but not prevent death of AGMs
from lethal HeV infection. In addition to severe respiratory
symptoms in all animals, prolonged disease progression in riba-
virin-treated animals was also marked by the appearance of
neurological symptoms.
MATERIALS AND METHODS
Viruses and cells. HeV was kindly provided by the Special Pathogens Branch
of the Centers for Disease Control and Prevention, Atlanta, GA. The virus was
propagated on Vero E6 cells in Dulbecco’s minimal essential medium (DMEM)
supplemented with 10% fetal calf serum (HyClone, Logan, UT), L-glutamine,
penicillin, and streptomycin at 37°C in a humidified CO2 incubator (5%). Virus
titration was performed using a 50% tissue culture infective dose (TCID50) assay
(tissue culture dose leading to 50% cytopathogenic effect) on 96-well plates (1 
104 Vero E6 cells per well) with a 100-l inoculum from 10-fold serial dilutions.
Plates were incubated for 3 days at 37°C, and wells were scored for cytopathic
effect (CPE). Virus concentrations were calculated as TCID50/ml. All infectious
work was performed in a class II biological safety cabinet in a biosafety level 4
(BSL4) laboratory at the Rocky Mountain Laboratories, Division of Intramural
Research, National Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health.
Animal infection. Twelve young adult African green monkeys (Chlorocebus
aethiops), weighing 5 to 7 kg (Three Springs Scientific, Inc., PA) were caged
individually. All animals were anesthetized by intramuscular injection of keta-
mine (10 to 15 mg/kg body weight) and inoculated intratracheally (i.t.) with 4 
105 TCID50 of HeV in 4 ml of DMEM on day 0. Nine animals were treated with
ribavirin subcutaneously (s.c.), starting with a loading dose of 50 mg/kg under
ketamine anesthesia, followed by a maintenance dose applied through s.c. injec-
tions of 10 mg/kg at 8-h intervals without anesthesia for 14 days or until animals
were euthanized. Three animals were treated with ribavirin beginning 24 h prior
to challenge, three animals received the initial ribavirin treatment beginning 12 h
after challenge, and three other animals received the initial ribavirin treatment
48 h after challenge. The dose regimen for ribavirin was based on the experience
with efficacy in NHPs for the treatment of Lassa fever virus infection (13).
Animals were anesthetized for clinical examination, temperature, respiration
rate, chest radiographs, blood draws, and swabs of nasal, oral, and rectal mucosa
on days 7, 1, 0, 1, 3, 5, 7, 10, and 12 p.i. All animals were euthanized when
clinical signs indicated terminal disease according to an endpoint scoring sheet.
Upon necropsy, various tissues were collected for virological assays. Experiments
were conducted under BSL4 conditions, and approval for animal experiments
was obtained from the Institutional Animal Care and Use Committee. Animal
work was performed by certified staff in an Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)-approved facility.
Sample collection. Nasal, oral, and rectal swabs were collected in 1 ml of
Dulbecco’s minimal essential medium (DMEM) (Sigma-Aldrich, St. Louis, MO)
and vortexed for 30 s. Whole blood was collected in EDTA Vacutainers (Beck-
man Dickinson, Franklin Lakes, NJ). Immediately following sampling, 140 l of
blood or 140 l DMEM from individual swab samples was added to 560 l of
AVL viral lysis buffer (Qiagen, Inc., Valencia, CA) for RNA extraction. For
tissues, approximately 100 mg was stored in 1 ml RNAlater (Qiagen, Inc.) for 7
days to stabilize RNA. RNAlater was completely removed, and tissues were
homogenized in 600 l RLT buffer (Qiagen, Inc.) in a 2-ml cryovial using Qiagen
tissue lyser and stainless steel beads. An aliquot representing approximately 30
mg was added to fresh RLT buffer (600-l final volume) for RNA extraction. The
tissues sampled include conjunctiva, tonsil, oro/nasopharynx, nasal mucosa, tra-
chea, right bronchus, left bronchus, right lung upper lobe, right lung middle lobe,
right lung lower lobe, right lung upper lobe, right lung middle lobe, right lung
lower lobe, bronchial lymph node (LN), heart, liver, spleen, kidney, adrenal
gland, pancreas, jejunum, colon transversum, brain (frontal and cerebellum),
brain stem, cervical spinal cord, pituitary gland, mandibular LN, salivary LN,
inguinal LN, axillary LN, mesenteric LN, urinary bladder, testes or ovaries, and
femoral bone marrow. All blood samples and swabs were inactivated in AVL
viral lysis buffer, and tissue samples were homogenized and inactivated in RLT
buffer prior to removal from the BSL4 laboratory. Subsequently, RNA was
isolated from blood and swabs using the QIAamp viral RNA kit (Qiagen, Inc.)
and from tissues using the RNeasy minikit (Qiagen, Inc.) according to the
manufacturer’s instructions supplied with each kit.
HeV TaqMan PCR. The HeV TaqMan assay was developed using primers and
probe that target the HeV nucleocapsid gene. The following HeV primers (high-
performance liquid chromatography [HPLC] purified) from Integrated DNA
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Technologies (San Diego, CA) were used: H1487F (CAT CGG AAA GAA ACC
CAC CTA A) and H1559 (GGT TTG GGT TCC TGG TCA TCT). The HeV
probe (Applied Biosystems, Carlsbad, CA) primer H1511comp had the sequence
6-carboxyfluorescein (6FAM)-TCC TGA GTC TGC CTG AGG GCG GT-6-
carboxytetramethylrhodamine (TAMRA). Ribosomal 18S primers and probe
were used as an internal control. Primer and probe sequences for 18S have been
described previously (18). One-step real-time PCR (RT-PCR) was done using
Rotor-Gene multiplex RT-PCR kits (Qiagen, Inc.). All RT-PCR mixtures con-
tained 2 l of RNA. Master mixes were set up following the manufacturer’s
protocols with the following primer and probe concentrations: HeV, 1 M
H1487F, 1 M H1559, and 0.25 M H1511; 18S, 0.05 M each primer and 0.2
M probe. Each reaction was done in a total volume of 25 l. HeV RNA
extracted from the inoculum (105 TCID50) was used as a positive control and as
a standard curve for each assay. Standards and test samples were assayed in
triplicate using the Rotor Gene 6000 detection system (Qiagen, Inc.) with the
following parameters: 50°C for 10 min, 95°C for 5 min, and 40 cycles of 95°C for
5 s and 60°C for 10 s. Threshold cycle (CT) values representing HeV nucleocapsid
(N) gene expression were analyzed with Rotor Gene 6000 software, and data are
shown as relative HeV N gene expression levels. For these data, a relative
expression unit of 1 represents 4.7 TCID50s of HeV inoculum.
Chest radiographs. A mobile digital radiography unit with a flat panel digital
detector (Sound Technologies tru/Dr) and a portable X-ray generator (Poskom
model PXP-HF) was used to acquire chest radiographs. The system operates on
veterinary-specific software system (Vetpacs). Animals were positioned for ven-
tral/dorsal radiography by using a Lexan V-shaped thoracic positioner. The
radiographic views acquired included ventral/dorsa, right lateral, and left lateral
thoracic images captured at peak inspiration while under anesthesia.
Hematology and blood biochemistry. Total white blood cell (WBC) count,
lymphocyte, platelet, reticulocyte, and red blood cell counts, hemoglobin, he-
matocrit values, mean cell volume, mean corpsular volume and mean corpuscu-
lar hemoglobin concentrations were determined from EDTA-blood with the
HemaVet 950FS laser-based hematology analyzer (Drew Scientific, Water-
bury, CT). Serum biochemistry was analyzed from heparin-blood using the blood
chemistry analyzer, iSTAT1 (Abbott Point of Care, Princeton, NJ). Using the
EC8 cartridge, blood urea nitrogen (BUN), glucose, chloride, sodium, potas-
sium, hematocrit, hemoglobin, pH, partial CO2 pressure (pCO2), total CO2
pressure (tCO2), base excess (BEecf), and anion gap values were determined;
creatinine values were evaluated using the Crea cartridges. Serum samples were
tested for concentrations of albumin (ALB), amylase (AMY), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), gamma-glutamyltransferase (GGT), glucose (GLU), cholesterol
(CHOL), total protein (TP), total bilirubin (TBIL), blood urea nitrogen (BUN),
and creatinine (CRE) by using a Piccolo point-of-care blood analyzer (Abaxis,
Sunnyvale, CA).
Virus titrations. Nasal, oral, and rectal swabs were collected and stored in 1 ml
of Dulbecco’s minimal essential medium (DMEM) and vortexed for 30 s. Whole
blood was collected in EDTA Vacutainers. Tissue samples were weighed and
homogenized in 10 equivalent volumes of DMEM to generate a 10% solution.
The solution was centrifuged at 10,000 rpm under aerosol containment in a
tabletop centrifuge for 5 min to pellet insoluble parts. All specimens were serially
diluted in DMEM, and 100-l volumes of each dilution were placed onto mono-
layers of Vero E6 cells in 96-well plates. Following a 3-day incubation at 37°C,
the plates were scored for CPE and the TCID50 was determined.
Histopathology and immunohistochemistry. A complete necropsy was per-
formed on all animals. Tissue samples of all major organs were collected from
each NHP for histopathologic and immunohistochemical examination and were
immersion fixed in 10% neutral buffered formalin for at least 7 days under BSL4
conditions. Prior to removal from the BSL4 conditions, formalin was changed
and specimens were processed under BSL2 conditions by conventional methods,
embedded in paraffin, and underwent sectioning at a 5-m thickness and hema-
toxylin and eosin or phosphotungstic acid-hematoxylin staining. Tissues for im-
munohistochemistry were stained on a Discovery XT automated stainer (Ven-
tana Medical Systems) using an anti-Nipah virus nucleocapsid protein antibody
FIG. 1. Average time to death. Shown is the therapeutic effect of
ribavirin treatment at 24 h prior to infection (pre) and 12 or 48 h
postinfection on the time to death. Black bars represent average time
to death for each group. Error bars represent the standard error of the
mean of three animals.







Untreated (PBS)a HeV1 5 7.5 NAb Nasal discharge, labored breathing
HeV6 6 8 NA Nasal discharge
HeV9 5 9.5 NA Nasal discharge
Ribavirin
24 h preinfection HeV10 7 10 7 Nasal discharge, muscle fasciculations
HeV11 6 10 NA Nasal discharge, labored breathing
HeV12 9 10.5 10 Nasal discharge, seizures
12 h p.i. HeV3 5 10 9 Muscle fasciculations
HeV4 5 10.5 9 Nasal discharge, muscle fasciculations
HeV5 7 10.5 NA Nasal discharge
48 h p.i. HeV2 5 9.5 9 Nasal discharge, muscle fasciculations
HeV7 5 10 9 Nasal discharge, muscle fasciculations, labored breathing
HeV8 5 8.5 NA Nasal discharge, labored breathing
a PBS, phosphate-buffered saline.
b NA, not applicable: no neurological symptoms were observed in these animals.
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(1:5,000) and the diaminobenzidine (DAB) map detection kit (Ventana Medical
Systems) (18). Nonimmune rabbit IgG was used as a negative staining control.
RESULTS
Ribavirin treatment of Hendra virus-infected African green
monkeys. Intratracheal inoculation of three untreated control
animals with 4  105 TCID50 HeV resulted in an average time
to death of 8.5 days (Fig. 1). Clinical signs included decreased
activity, piloerection of body hair, and mild depression as early
as 5 days postinfection (p.i.) (Table 1). Rapidly progressive
clinical illness was observed on day 7 or 9, with clinical signs
including severe depression, severely reduced ability to move,
and signs of respiratory disease (e.g., labored breathing, nasal
discharge). According to a predetermined clinical endpoint
scoring sheet and in consultation with a veterinarian, animals
were euthanized when acute respiratory distress was obvious
(as early as 7 days p.i.).
Treatment with ribavirin 24 h prior to or 12 h after challenge
resulted in a significant delay in time to death (2 days),
whereas no effect was observed in animals treated 48 h p.i.
(Fig. 1). Interestingly, the delay in death shifted the disease
manifestations from primarily respiratory to neurological
symptoms (Table 1). Neurological symptoms included muscle
fasciculations of the arms and face as well as seizures progres-
sively increasing in length, severity, and occurrence. The ma-
jority of animals started exhibiting neurological symptoms on
day 9 p.i., which progressed until animals were euthanized
based on a predetermined humane endpoint scoring sheet,
although one animal showed neurological symptoms as early as
day 7 p.i.
Blood biochemistry results included increased BUN and glu-
cose levels and decreased albumin and total protein levels
(data not shown).
Radiological and gross pathological changes. Respiratory
disease development was analyzed by radiographic imaging (X
ray), with the first signs of infiltration and interstitial markings
in the lungs of some infected animals on day 7 p.i. (Fig. 2). This
developed into diffuse interstitial infiltrates and cardiac border
effacement with areas of pulmonary consolidation. Radiologi-
cal changes were more severe in the control group and animals
treated with ribavirin 48 h p.i.
Gross pathological changes observed during necropsies in-
cluded sanguinous discharge from the nares (Fig. 3A) and
severe lesions in the lungs, with affected lung lobes appearing
plum colored, firm on palpation, and heavy and wet as signs for
edema (Fig. 3B). Serous fluid was observed in the thoracic
cavity in these animals. In agreement with the radiological
changes, the percentage of affected lung lobes appeared larger
in the control and 48-h treatment groups compared to the
24-h and 12-h treatment groups.
FIG. 2. Radiological and gross pathological changes in lungs of Hendra virus-infected African green monkeys. Radiologic progression of
respiratory disease in animal HeV6 (Table 1), who was euthanized on day 8 due to severe respiratory distress. First evidence of congestion is
observed on day 7 p.i., and infection rapidly progressed to diffuse interstitial infiltrates and pulmonary consolidation by day 8 p.i. R, right side.
FIG. 3. Gross pathological changes observed during HeV infection of African green monkeys. Shown are gross pathological changes associated
with the end stage of lethal HeV infection in African green monkeys. (A) Sanguinous froth exuding from nares; (B) enlarged lungs with multifocal
areas of congestion and hemorrhage; (C) congestion of the brain (black arrows).
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Other gross pathological changes included enlarged cervical
and bronchial lymph nodes, enlarged spleen, congested liver,
and inflammation in the gastrointestinal tract (data not
shown). In agreement with the observation of neurological
symptoms, severe congestion of vessels in the brain was also
present in several animals (Fig. 3C).
Histopathological changes in Hendra virus-infected African
green monkeys. In agreement with the clinical presentation,
radiological changes and gross pathological changes, intratra-
cheal infection of AGM with HeV resulted in histopathology
comparable to an acute respiratory distress syndrome (ARDS),
including alveolar hemorrhaging, pulmonary edema, and in-
flammation. Injury to the gas exchange region in the lungs
consisted of alveolitis, interstitial edema, and congestion in the
alveolar septa and around small blood vessels. An abundance
of polymerized fibrin was observed throughout the alveolar
spaces (Fig. 4A). Endothelial syncytial cells were particularly
prominent, and HeV antigen was primarily detected in the
alveolar walls as well as the endothelium of small blood vessels
(Fig. 4B). In the brain, HeV antigen was present in endothelial
cells as well as in widespread areas of neurons (Fig. 4C and D).
Interestingly, HeV antigen could be detected in the brain of
animals with and without neurological symptoms.
Hendra virus replication in African green monkeys. To as-
sess the dissemination and tissue tropism of HeV, infectious
virus titers were determined in nasal, oral, and rectal swabs as
well as in blood and a variety of tissues sampled at necropsy. In
addition, these samples were also tested for presence of viral
RNA by quantitative RT-PCR. Infectious virus could be re-
covered in a variety of tissues of control animals, including
tissues throughout the respiratory tract, heart, liver, spleen,
kidney, and a variety of lymph nodes (Fig. 5A). Interestingly,
while ribavirin treatment did not protect against lethal HeV
infection, virus titers and the number of tissues positive for
FIG. 4. Histological changes and tropism of HeV in tissues from infected African green monkeys. Shown are histological changes associated
with the end stage of lethal HeV infection in African green monkeys (animal HeV1; Table 1). (A) Phosphotungstic acid-hematoxylin (PTAH)
staining of lung lobe showing an abundance of polymerized fibrin in and around the alveolar spaces; (B) localization of HeV antigen by
immunohistochemical (IHC) stain in the alveolar septae and within a lung blood vessel showing endothelial syncytia (inset); (C) IHC stain of HeV
antigen in the brain stem; (D) detection of HeV antigen in neuron cell body and axon as well as surrounding cells.
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infectious virus were lower in animals treated 24 h prior to
infection as compared to the controls. The primary tissues
affected were the respiratory tract, spleen, kidney, brain stem,
pituitary gland, and several lymph nodes. In addition, ribavirin
treatment at 12 and 48 h postinfection also resulted in lower
titers but not a reduction in the number of virus-positive tis-
sues. While neurological symptoms were apparent in all riba-
virin-treated groups, recovery of infectious virus from the cen-
tral nervous system was variable and included infectious virus
in the brain stem, pituitary gland, and cerebellum.
Low titers of infectious virus could also be detected in blood
samples and oral, nasal, and rectal swabs of individual animals,
but results were inconsistent with regard to treatment, samples
and time postinfection (data not shown). Viral RNA was de-
tectable in all organ tissues at variable levels (Fig. 5B). The
highest relative viral RNA expression was detected in the lung
tissue of infected animals, with no difference observed between
the treatment groups. In addition, low levels of viral RNA were
also detected in oral, nasal, rectal, and blood samples increas-
ing over time (Fig. 6).
DISCUSSION
The henipaviruses are newly emerging zoonotic viruses that
can cause severe respiratory illness and encephalitis in humans
(14). Despite intensive studies, there are still no licensed vac-
cines or antiviral therapies for henipavirus infections. The goal
of the present study was to develop a new NHP disease model
to study the pathogenesis of lethal HeV infection and assess
the efficacy of ribavirin as an antiviral treatment.
While several animals models have been described for both
HeV and the related NiV, studies on pathogenesis and the
development of effective therapeutics have been somewhat
limited due to biocontainment restriction for work with the
infectious pathogens and the absence of reagents for some
animal species (25).
In the present study, we demonstrated that intratracheal
inoculation of HeV in AGM results in a uniformly lethal in-
fection within 7 to 9 days displaying largely as an acute respi-
ratory distress syndrome (ARDS). The animals developed ex-
tensive diffuse interstitial infiltrates, as shown by radiological
analysis, only 1 to 2 days prior to death. Upon necropsies,
FIG. 5. Virus replication in tissues of HeV-infected African green monkeys. Virus replication was determined in tissues of HeV-infected
animals by virus titration (A) and TaqMan RT-PCR (B) as described in Materials and Methods. For each treatment group, tissue samples from
three animals were assayed and analyzed and the mean TCID50 or relative HeV N expression values were calculated. The error bars represent the
standard error of the mean. The TCID50 titers are calculated per gram (gr) of tissue. LN, lymph node.
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severe lung lesions were observed covering up to 90% of the
tissue. Histopathological changes were primarily found in the
lung and included alveolar hemorrhage, pulmonary edema,
inflammation, and syncytial vascular endothelium, similar to
what has been described in human cases of both HeV and NiV
(27, 28). This is the first NHP disease model developed for
HeV infection. Similar results were obtained when AGMs
were infected with NiV (9), showing that this specific NHP
species is a good and robust model for studying henipavirus
infection. Recently NiV infection was described in squirrel
monkeys (17). After intranasal or intravenous inoculation with
NiV at high doses, several animals showed clinical signs, in-
cluding acute respiratory distress and neurological symptoms;
however, more than 50% of the animals either recovered or
showed no symptoms. Although intravenous inoculation ap-
peared more efficient than intranasal infection in establishing a
symptomatic infection, NiV and HeV infection most likely
occurs per os or through inhalation of contaminated fluids;
thus, an intratracheal inoculation will be closer to the natural
route of infection (12, 15, 16).
To date, only a limited number of human cases of HeV
infection have been identified. Like in the AGM model, all
human cases initially presented with ILI symptoms (22, 23, 27).
In half of the cases, the disease progressed to neurological
symptoms. During the outbreak of HeV in Australia in the
summer of 2009, one individual died while receiving ribavirin
treatment and three people with extensive exposure to the
nasal secretions or blood of confirmed or highly suspected
equine cases were admitted to hospital for a 5-day course of
prophylaxis comprising intravenous ribavirin and oral chloro-
quine (ProMed-mail no. 20090826.2998). While these three
people were released without developing any clinical symp-
toms after treatment, HeV infection was never confirmed.
Therefore, whether ribavirin treatment is effective against
HeV infection remains unknown.
The antiviral efficacy of ribavirin against henipaviruses has
been shown in several in vitro studies; however, in vivo studies
have had varied outcomes (1, 2, 8, 29). While ribavirin treat-
ment in hamsters was not protective against lethal HeV chal-
lenge (8), an open-label ribavirin treatment trial run during an
NiV outbreak in Malaysia in 1998 reported a reduction in
mortality by 36% (6). Therefore, we used our newly developed
AGM model to test the efficacy of ribavirin treatment against
a lethal challenge with HeV.
Ribavirin treatment has been successfully used in a rhesus
macaque model of Lassa virus infection (13). Using a similar
FIG. 6. Virus detection in samples from HeV-infected African green monkeys. TaqMan RT-PCR was used to determine the relative HeV N
expression levels in oral (A), nasal (B), and rectal (C) swabs as well as in whole blood (D) on days 1, 3, 5, 7, and 9 postinfection. For each treatment
group, samples from three animals were assayed and analyzed and the mean relative HeV N expression values were calculated. The error bars
represent the standard error of the mean.
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therapeutic regiment, we treated three groups of three animals
with ribavirin three times daily throughout the study, starting
either 24 h prior to challenge or 12 or 48 h postchallenge.
While none of the treatments protected against lethal HeV
challenge, the 24-h pretreatments and 12-h posttreatments did
significantly delay the time to death, similarly to what was seen
in hamsters (8). In addition, the ribavirin treatment reduced
the levels of viral replication, as seen in the Lassa virus model
(13). Interestingly, the delay in time to death resulted in the
development of neurological symptoms, including, among oth-
ers, muscle fasciculations and seizures. The ribavirin treatment
effectively lowered virus titers which apparently precluded the
development of respiratory symptoms. The treatment did not
seem to prevent systemic spread of the virus, and therefore
infection of the central nervous system (CNS) could be estab-
lished. As ribavirin does not cross the blood-brain barrier, no
therapeutic benefit would be expected once CNS infection has
occured. Similar results have been shown in Junin virus-in-
fected rhesus monkeys, where ribavirin treatment increased
the mean time to death and induced neurological symptoms
(19, 26).
While neurological symptoms were not seen in HeV-in-
fected control AGMs, these animals succumbed to an acute
onset of respiratory distress before virus-associated clinical
symptoms from infection of the central nervous system became
obvious. By lowering the viral dose through ribavirin treatment
systemically, respiratory symptoms are less pronounced, but
spread to the CNS is not affected, resulting in the appearance
of neurological symptoms. Similar results were observed in
hamsters and ferrets, where a low dose of NiV or HeV resulted
in a longer mean time to death and more neurological symp-
toms, whereas a high dose resulted in the rapid development of
severe respiratory distress (unpublished data). Therefore, low-
ering but not clearing HeV systemically will result in the de-
velopment of both respiratory and neurological symptoms,
with the neurological symptoms becoming more pronounced.
Based on the data here, ribavirin treatment does not seem to
be effective against lethal HeV infection. While there are cur-
rently no approved treatments, several treatment and vaccine
candidates have been evaluated using rodent, cat, and ferret
models. The most successful treatment strategy reported to
date makes use of the cross-neutralizing, fully human mono-
clonal antibody m102.4 (5, 30). This passive antibody treat-
ment proved fully protective when a single dose was adminis-
tered 10 h postchallenge in a ferret model of lethal NiV
infection. In addition, a vaccination boost strategy using a
recombinant soluble attachment glycoprotein (sG) from either
HeV or NiV has shown protective efficacy against lethal NiV
challenge in cats (18, 20). Both of these intervention strategies
are currently being evaluated using the recently developed
AGM models for lethal HeV and NiV infection.
In conclusion, our data show that AGMs can be efficiently
infected with HeV and the disease progression closely mirrors
that seen in human cases. We believe that this new model will
be a powerful tool for studying the pathogenesis of HeV in-
fection as well as an essential model for the development of
vaccines and therapeutics in the future. This study demon-
strated that ribavirin can delay clinical progression of HeV
infection but does not prevent lethal outcome. Therefore, we
propose that ribavirin is of limited efficacy for HeV infection,
and given the sometimes severe side affects associated with
ribavirin and the potential for developing an encephalitic syn-
drome, it may not be recommended as a single therapy for
HeV infections. Efficacy may increase in combination therapy
with other treatment modalities such as drugs or antibodies (4,
5). However, this remains to be investigated before recommen-
dations can be made.
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